Compare MMLP & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMLP | ASRT |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.8M | 76.0M |
| IPO Year | 2002 | 2004 |
| Metric | MMLP | ASRT |
|---|---|---|
| Price | $2.41 | $23.44 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $18.00 |
| AVG Volume (30 Days) | 26.2K | ★ 455.2K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,009,000.00 | $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $2.21 | $0.60 |
| 52 Week High | $3.54 | $23.46 |
| Indicator | MMLP | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 84.78 |
| Support Level | $2.24 | $0.70 |
| Resistance Level | $2.80 | N/A |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 26.53 | 98.18 |
Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.